Compare CDP & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDP | CELC |
|---|---|---|
| Founded | 1988 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.1B |
| IPO Year | N/A | 2017 |
| Metric | CDP | CELC |
|---|---|---|
| Price | $29.63 | $106.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $33.29 | ★ $100.13 |
| AVG Volume (30 Days) | ★ 882.8K | 874.9K |
| Earning Date | 10-30-2025 | 11-12-2025 |
| Dividend Yield | ★ 4.11% | N/A |
| EPS Growth | ★ 9.45 | N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | ★ $752,757,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.48 | N/A |
| P/E Ratio | $22.46 | ★ N/A |
| Revenue Growth | ★ 0.43 | N/A |
| 52 Week Low | $23.92 | $7.58 |
| 52 Week High | $33.49 | $107.04 |
| Indicator | CDP | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 51.80 | 78.81 |
| Support Level | $29.59 | $96.70 |
| Resistance Level | $30.99 | $102.58 |
| Average True Range (ATR) | 0.58 | 5.73 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 46.85 | 98.67 |
COPT Defense Properties is a fully-integrated and self-managed real estate investment trust (REIT) focused on owning, operating and developing properties in locations proximate to, or sometimes containing, key U.S. Government (USG) defense installations and missions. Its tenants include the USG and their defense contractors, who are engaged in priority national security activities, and who generally require mission-critical and high security property enhancements. Its properties include 195 operating properties totaling approximately 22.4 million square feet comprised of 16.5 million square feet in 164 office properties and 5.9 million square feet in 31 single-tenant data center shells.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.